Research

ZUPREME-1 Phase 2 results, published in The Lancet, show petrelintide cut body weight by up to 10.7% with placebo-comparable GI tolerability.

Phase 2 ASPEN-06 data published in Nature Medicine show evorpacept doubling response rates in CD47-high, HER2-retained gastric cancer patients.

Addex reported a net loss of CHF 3.5m for the first half of 2026, with cash at CHF 0.8m after an ATM raise

Real-world SwissNET registry data showed patients re-treated with 177Lu-edotreotide achieved nearly triple the median overall survival of those switched to

The preclinical joint venture presented its α-Klotho cell-encapsulation programme at a Miami longevity conference, outlining progress on a GMP cell bank.

Kessler Foundation and UPnRIDE are studying real-world use of the FDA-cleared standing mobility platform among rehabilitation patients.

Biomarker data from two trials support cemsidomide's T-cell activating mechanism, as the 75 µg dose combination with elranatamab clears safety review.

The Alabama biotech has made its first payment to Mount Sinai under a clinical agreement, with enrollment in the 150-patient SHIELD trial expected shortly.

Kraig Biocraft says finishing its Atlas Gene Library unlocks over 200 genetic configurations in its pursuit of advanced spider silk fibres.

Exploratory subgroup analyses from two trials showed fasedienol reduced anxiety symptoms in participants with very severe social anxiety disorder.

Absci will launch a global, placebo-controlled Phase 2 study of its AI-designed anti-PRLR antibody ABS-201 in endometriosis patients from mid-2027.

Nanobiotix posted H1 2026 results showing encouraging NBTXR3 response rates in lung and head and neck cancer trials, backed by a freshly raised €86 million.

The San Diego siRNA biotech raised up to $535m including an AbbVie cornerstone placement, valuing one of 2026's larger biotech listings.

Addex Therapeutics has reclaimed its full GABAB positive allosteric modulator portfolio from Indivior, citing the UK firm's R&D rationalisation ahead of a planned

Avacta Therapeutics shared preclinical PDX data and Phase 1 trial design for its FAP-targeted peptide-drug conjugate AVA6103 at the AACR pancreatic cancer conference.

Firefly Neuroscience will introduce NeuroSigma's Monarch eTNS sleep-worn neurostimulator to its US clinician network as a non-drug ADHD option for children.

A Washington University cohort study used Alamar's 130-protein plasma panel to show amyloid clearance and cognitive response reflect distinct biological processes.

Transgene's personalised neoantigen vaccine TG4050 maintained 100% disease-free survival at over three years in resected head and neck cancer, with Phase 2 topline

The Bristol biotech will lead an international consortium to engineer red blood cells that sense and respond to physiological changes.

Envisagenics' AI-powered SpliceCore platform will supply tumour-specific targets to Boehringer across ADC, T-cell engager and multispecific antibody programmes.